Food and Drug Administration

Florida Gets Green Light from FDA to Import Prescription Drugs from Canada: A Potential Game-Changer for U.S. Healthcare Costs

The U.S. Food and Drug Administration (FDA) recently authorized Florida’s Agency for Health Care Administration to import certain prescription drugs from Canada under section 804 of the Federal Food, Drug, …

Florida Gets Green Light from FDA to Import Prescription Drugs from Canada: A Potential Game-Changer for U.S. Healthcare Costs Read More
Federal Trade Commission

FTC Finalizes Consent Order in Amgen’s Acquisition of Horizon Therapeutics, Ensuring Continued Pharmaceutical Competition

The Federal Trade Commission (FTC) has recently finalized a consent order that resolves potential competition issues arising from Amgen Inc.’s acquisition of Horizon Therapeutics plc. This follows the dismissal of …

FTC Finalizes Consent Order in Amgen’s Acquisition of Horizon Therapeutics, Ensuring Continued Pharmaceutical Competition Read More

Federal Trade Commission

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics

The Federal Trade Commission (FTC) recently announced that it has moved to dismiss its case against pharmaceutical giant Sanofi following the company’s decision to terminate its proposed acquisition of an …

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics Read More
Prescription

Pennsylvania House Passes Bill Safeguarding Prescription Coverage for Seniors Amid Social Security Hike

PENNSYLVANIA — In a crucial move aimed at protecting older Pennsylvanians’ access to vital prescription medication programs, the state House approved legislation on Wednesday. The bill, introduced by Sen. Judy …

Pennsylvania House Passes Bill Safeguarding Prescription Coverage for Seniors Amid Social Security Hike Read More

Federal Trade Commission

FTC Files Amicus Brief Highlighting Anticompetitive Harm from Improperly Listed Patents in FDA’s ‘Orange Book’

The Federal Trade Commission (FTC) filed an amicus brief on November 20, 2023, addressing the anticompetitive harm resulting from improperly listed patents in the Food and Drug Administration’s (FDA) “Approved …

FTC Files Amicus Brief Highlighting Anticompetitive Harm from Improperly Listed Patents in FDA’s ‘Orange Book’ Read More